Further analyses by immunohistochemical experiments showed that the number of tumor cells positive for Ki-67 was substantially less in LMS tumors treated with the combination treatment compared with tumors treated with either drug alone or control tumors (Figure 8C). The gene discussed is MKI67; the disease is neoplasm.